Royce & Associates LP lessened its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 32.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 224,754 shares of the specialty pharmaceutical company’s stock after selling 107,311 shares during the period. Royce & Associates LP owned 0.69% of Collegium Pharmaceutical worth $4,904,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Freestone Grove Partners LP bought a new position in Collegium Pharmaceutical during the 2nd quarter worth approximately $1,611,000. Globeflex Capital L P purchased a new position in Collegium Pharmaceutical in the 2nd quarter worth approximately $1,915,000. Bank of America Corp DE purchased a new position in Collegium Pharmaceutical in the 2nd quarter worth approximately $9,882,000. Empowered Funds LLC bought a new stake in Collegium Pharmaceutical in the second quarter valued at approximately $2,045,000. Finally, Bank of New York Mellon Corp bought a new stake in Collegium Pharmaceutical in the second quarter valued at approximately $8,506,000.
Analyst Ratings Changes
A number of brokerages have issued reports on COLL. Leerink Partners began coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, November 6th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Sunday. Weiss Ratings upgraded shares of Collegium Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, November 9th. Finally, Needham & Company LLC cut their target price on Collegium Pharmaceutical from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, November 5th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.00.
Get Our Latest Report on Collegium Pharmaceutical
Collegium Pharmaceutical Stock Up 1.5%
COLL stock opened at $25.93 on Thursday. The business has a 50 day moving average of $23.17 and a 200 day moving average of $31.97. The firm has a market cap of $805.90 million, a PE ratio of 3.85, a price-to-earnings-growth ratio of 0.79 and a beta of 0.75. Collegium Pharmaceutical, Inc. has a twelve month low of $21.43 and a twelve month high of $50.79. The company has a quick ratio of 0.87, a current ratio of 1.01 and a debt-to-equity ratio of 3.44.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.10. Collegium Pharmaceutical had a net margin of 4.68% and a return on equity of 85.14%. The company had revenue of $216.34 million during the quarter, compared to analyst estimates of $216.03 million. During the same period in the previous year, the business earned $2.25 EPS. The firm’s revenue for the quarter was up 67.4% on a year-over-year basis. On average, research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current fiscal year.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.
See Also
- Five stocks we like better than Collegium Pharmaceutical
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report).
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
